Concept
Safety Outlook
ASCO 2026: Lung Cancer Treatment Options, New Studies - Cancer Therapy Advisor / TRITON: Tremelimumab Plus Durvalumab and Chemotherapy
"The incidence of adverse events was similar between the treatment arms, with low rates of discontinuation and no new safety signals, he said. The incidence of adverse events was similar between the 2 study arms, with TRAEs leading to 3 treatment discontinuations (1 in the D+T+CT group and 2 in the P+CT group) and 1 patient death (in the P+CT group). “With larger numbers and longer follow-up, we may have a clearer sense of whether CTLA-4-containing regimens can meaningfully improve outcomes for these molecularly defined subgroups,” Dr Schoenfeld said. “There’s certainly an unmet need for treating tumors harboring mutations like STK11 and KEAP1 that appear to confer some degree of resistance to immunotherapy,” agreed Dr Neal."
Related Ideas
- TRITON FindingsASCO 2026: Lung Cancer Treatment Options, New Studies - Cancer Therapy Advisor · TRITON: Tremelimumab Plus Durvalumab and Chemotherapy
- Safety SignalsASCO 2026: Lung Cancer Treatment Options, New Studies - Cancer Therapy Advisor · ROSETTA Lung-02: Pumitamig
- Safety ProfileASCO 2026: Lung Cancer Treatment Options, New Studies - Cancer Therapy Advisor · CHRYSALIS-2: First-Line Amivantamab Plus Lazertinib
- Safety ProfileASCO 2026: Lung Cancer Treatment Options, New Studies - Cancer Therapy Advisor · CROWN: 7-Year Update for Lorlatinib
- Pumitamig TherapyASCO 2026: Lung Cancer Treatment Options, New Studies - Cancer Therapy Advisor · ROSETTA Lung-02: Pumitamig
- Response RatesASCO 2026: Lung Cancer Treatment Options, New Studies - Cancer Therapy Advisor · ROSETTA Lung-02: Pumitamig
- Immunotherapy ReachCancer in 2026: How Immunotherapy Is Reshaping the Odds - Cancer Research Institute · What the Report Means for Immunotherapy
- Melanoma ProgressCancer in 2026: How Immunotherapy Is Reshaping the Odds - Cancer Research Institute · Immunotherapy Is Helping Rewrite Survival Curves